NAION and GLP-1 Medications: What Patients Should Know
GLP-1 medications have become important treatments for type 2 diabetes and obesity. They can help improve blood sugar control, support meaningful weight loss, and, for many patients, reduce the risk of cardiovascular, kidney, and other complications.
In November 2026, the U.S. Food and Drug Administration (FDA) announced a new safety warning concerning a rare eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION. The FDA is now requiring all GLP-1 medications to include information about a potential increased risk of NAION in their prescribing information.
This includes widely used medications such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, and Saxenda, among others.
What is NAION?
NAION occurs when the optic nerve, which carries visual information from the eye to the brain, does not receive enough blood flow.
It typically causes a sudden, painless change in vision in one eye. Someone may notice blurred or dimmed vision, a dark or missing area in their field of vision, altered color vision, or a sudden loss of part of their vision. Symptoms are often first noticed upon waking.
The amount of vision affected varies. Some people experience partial improvement, but vision loss can be permanent. At present, there is no treatment proven to reliably restore vision that has been lost from NAION.
Why Did the FDA Issue a Warning?
Concerns about a possible connection initially arose from studies involving semaglutide, the medication in Ozempic, Wegovy, and Rybelsus.
Since then, researchers and regulators have examined GLP-1 medications more broadly. The FDA reviewed randomized clinical trials, large real-world databases, published studies, and reports of NAION in people taking these medications.
Importantly, cases have now been reported with all currently marketed GLP-1 medications, leading the FDA to require the warning for the entire class rather than for semaglutide alone.
This does not prove that GLP-1 medications directly cause NAION. However, the available evidence was strong enough for the FDA to conclude that patients and physicians should be aware of a potential increased risk.
How Large is the Risk?
The good news is that NAION remains very rare.
In the FDA’s analysis of 126 randomized clinical trials, NAION occurred at a rate of approximately 6.4 cases per 100,000 treatment-years among people taking GLP-1 medications, compared with approximately 3.8 cases per 100,000 treatment-years among people receiving placebo or other treatments.
Put more simply, even if GLP-1 medications increase the risk, the additional number of cases appears to be quite small.
Other studies have produced somewhat different estimates, particularly among patients with diabetes who already have a greater underlying risk of NAION. For that reason, we cannot yet give an exact risk for any individual patient.
Do GLP-1 Medications Cause NAION?
We still do not know for certain.
The FDA’s review supports an association between GLP-1 medications and NAION, but it did not identify a clear biological explanation for why these medications might cause the condition. Some studies have also produced conflicting results.
There is another challenge: many people taking GLP-1 medications already have conditions that independently increase their risk of NAION. These include diabetes, high blood pressure, obstructive sleep apnea, smoking, anemia, and kidney disease. Someone who has already experienced NAION in one eye also has an increased risk of developing it in the other eye.
For now, it is most accurate to say that GLP-1 medications appear to be associated with a small potential increase in the risk of NAION, but researchers are still determining precisely why this occurs and which patients are most susceptible.
What Does This Mean If You Take A GLP-1 Medication?
For most patients, the FDA warning is not a reason to automatically stop treatment.
GLP-1 medications can provide substantial benefits, including weight loss, improved diabetes control, and reductions in cardiovascular and kidney complications. Those benefits need to be weighed against a serious but very uncommon potential side effect.
Patients should speak with their physician about their individual risk, particularly if they have previously experienced NAION, have significant underlying eye disease, or have other risk factors.
Patients should not stop a GLP-1 medication on their own solely because of the new warning.
However, if NAION does occur, the FDA now recommends that physicians consider discontinuing the GLP-1 medication unless the benefits of continuing treatment clearly outweigh the risk.
When Should You Seek Medical Attention?
Any sudden or significant change in vision in one eye should be evaluated promptly.
Symptoms that warrant immediate attention include sudden, painless vision loss; a new dark, gray, or missing area in the visual field; tunnel vision; changes in color vision; or an unexplained area of blurred or hazy vision.
The FDA recommends contacting a healthcare professional immediately if these symptoms develop. If NAION is suspected, prompt evaluation by an ophthalmologist is appropriate.
Sudden vision loss can also have causes other than NAION, some of which require immediate treatment, making timely evaluation particularly important.
The Bottom Line
The FDA’s new warning represents an important development in what we know about GLP-1 medications and NAION.
There is now enough evidence for the FDA to recognize a potential increased risk of NAION across the GLP-1 medication class, rather than focusing only on semaglutide. At the same time, NAION remains rare, the absolute increase in risk appears small, and a direct cause-and-effect relationship has not been fully established.
For most patients, the benefits of GLP-1 therapy are likely to continue to outweigh this uncommon risk. Treatment decisions should be individualized based on a patient’s medical history, underlying risk factors, and the benefits they are receiving from the medication.
Most importantly, patients taking a GLP-1 medication should be aware of the symptoms and seek prompt medical attention for any sudden or significant change in vision.
